 |
|
|
| |
BASELINE CLINICAL AND LABORATORY PARAMETERS ASSOCIATED WITH CLINICAL BENEFITS OF SUCCESSFUL HCVTREATMENT WITH SOFOSBUVIR/VELPATASVIR IN DECOMPENSATED CIRRHOTIC PATIENTS
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Jacqueline O'Leary* 1, Robert S. Brown2, K R. Reddy3, Jonathan Fenkel4, Kevin Korenblat5, Ziad H. Younes6, Robert Herring7, Di An8, Anu Osinusi8, John McNally8, Diana Brainard8, John McHutchison8, Michael P. Curry9, Michael Charlton10
1Baylor University Medical Center, Dallas, 2Weill Cornell Medical College,, New York, 3University of Pennsylvania School of Medicine,, 4Thomas Jefferson University, Philadelphia, 5Washington University School of Medicine, Saint Louis, 6Gastro One Medical Centre,, Germantown, 7Quality Medical Research Center, Nashville, 8Gilead Sciences Inc, Foster City, 9Beth Israel Deaconess Medical Center, Boston, 10Intermountain Medical Center, Salt Lake City, United States
|
| |
|
|
|
|
|
